Dogwood Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Dogwood Therapeutics reports significant R&D investment and clinical trial progress for its pain and neuropathy pipeline, alongside substantial net losses and ongoing capital needs.
NASDAQ
Dogwood Therapeutics' 2024 10-K filing highlights its focus on developing Halneuron for chemotherapy-induced neuropathic pain and antiviral therapies for fibromyalgia and Long-COVID, while addressing concerns about its ability to continue as a going concern.
NASDAQ
10-K/A: Virios Therapeutics Amends Annual Report to Correct Auditor Statement, Reaffirms Financial Controls
Virios Therapeutics files an amendment to its annual report to include a missing sentence in the auditor's opinion and reaffirms the accuracy of its financial statements and internal controls.
NASDAQ
Virios Therapeutics' 2023 10-K filing highlights ongoing clinical development of IMC-1 and IMC-2, along with financial challenges and the need for additional capital.